Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Note 4 - Balance Sheet Components (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
Note 4 - Balance Sheet Components (Details Textual)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions	11		11		4
Interest Receivable	$ 200,000		$ 200,000		$ 200,000
Debt Securities, Available-for-Sale, Gain (Loss)			0		0
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0		0		0
Accounts Receivable, Allowance for Credit Loss	0		0		0
Unbilled Receivables, Current	46,981,000		46,981,000		36,781,000
Depreciation	800,000	$ 900,000	1,700,000	$ 1,800,000
Tangible Asset Impairment Charges	0	0	0	0
Prepaid Expense Other, Noncurrent	25,218,000		25,218,000		25,218,000
Operating Lease, Right-of-Use Asset	10,230,000		10,230,000		11,432,000
Intangible Asset, Finite-Lived, Amortization Expense	200,000	$ 200,000	400,000	$ 400,000
Goodwill	4,508,000		4,508,000		4,508,000
Goodwill, Impairment Loss			0
Accounts Payable	17,000,000		$ 17,000,000		$ 21,500,000
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			3 years 4 months 24 days
Intellectual Property [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			1 year 6 months
Customer Concentration Risk [Member] \| Prepaid Expenses [Member] \| Clinical Research Organization [Member]
Concentration Risk, Percentage			51.00%		90.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Clinical Research Organization [Member]
Concentration Risk, Percentage			28.00%		66.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Analytical Testing Vendor [Member]
Concentration Risk, Percentage			58.00%		28.00%
Customer Concentration Risk [Member] \| Other Accrued Liabilities [Member] \| Clinical Research Organization [Member]
Concentration Risk, Percentage			81.00%		79.00%
BARDA [Member]
Unbilled Receivables, Current	47,000,000		$ 47,000,000		$ 36,800,000
Royalty [Member]
Prepaid Royalties	$ 11,000		$ 11,000		300,000
Government Contract [Member]
Accounts Receivable, after Allowance for Credit Loss					14,600,000
Government Contract [Member] \| HHS Barda [Member]
Accounts Receivable, after Allowance for Credit Loss					$ 14,200,000